A 31% stock gain since launching the 5×30 strategy is the number Pacira’s board keeps returning to, and with good reason — it’s the strongest rebuttal available against DOMA Perpetual Capital Management’s proxy challenge ahead of the June 9 annual meeting. What makes this fight structurally interesting isn’t the typical activist-versus-incumbent drama; it’s that Pacira is genuinely defending a position of improving fundamentals, not papering over deterioration. Record revenues of $726.4 million in 2025, GAAP gross margins of 79.4%, and EXPAREL volume growth accelerating from 3.6% to 6.2% year-over-year are not cosmetic numbers. The board isn’t asking shareholders to trust a turnaround promise — it’s asking them to not interrupt one mid-execution.
The EXPAREL IP settlement with Fresenius Kabi is the strategic hinge most observers underweight. Full exclusivity through 2030 with a capped, gradual generic transition extending to 2039 removes the cliff-edge dynamic that typically forces a branded pharmaceutical company into desperate M&A or deep cost cuts. That runway is what makes the 5×30 diversification plan credible rather than aspirational. Pacira has room to let PCRX-201, the intra-articular gene therapy for osteoarthritis, and the in-licensed ropivacaine asset PCRX-2002 mature through Phase 2 without the revenue floor collapsing beneath them. The J&J MedTech and LG Chem partnerships tripling U.S. physician reach aren’t vanity deals — they’re distribution infrastructure being laid while EXPAREL still funds the P&L.
DOMA’s argument, stripped of the proxy-contest noise, appears to be that the board overseeing years of prior underperformance lacks the credibility to execute the current plan. That’s a legitimate governance question, but it collides with an uncomfortable fact: the plan is working, and the three Phase 2 data readouts expected before year-end represent exactly the kind of pipeline optionality that activist investors typically demand, not resist. Replacing three board nominees now injects uncertainty into a leadership structure that has produced 16 months of measurable progress.
The single metric that will render a verdict on both sides: EXPAREL volume growth in the second half of 2026. Management has explicitly committed to convergence between volume and sales growth starting then — a specific, falsifiable claim. If that convergence materializes, DOMA’s thesis collapses entirely and the 5×30 framework earns the institutional credibility it needs to survive beyond this proxy fight.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
